Ophthalmology Center of Excellence

Supporting patients living with a rare ophthalmology condition

Orsini’s Ophthalmology Center of Excellence launched in 2020 with our first program for progressive keratoconus. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Ophthalmology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Ophthalmology Conditions Supported

Explore the ophthalmology conditions and therapies Orsini supports below.

About Corneal Ectasia

Corneal ectasia is a condition characterized by progressive thinning and bulging of the cornea, the transparent front part of the eye. Commonly associated with conditions like keratoconus, post-LASIK surgery complications, or corneal degeneration, corneal ectasia results in an altered corneal shape, impacting vision. Symptoms include blurred or distorted vision, sensitivity to light, and difficulty with night vision.

Corneal Ectasia Therapies Supported

Full Name	Photrexa® (riboflavin 5’-phosphate ophthalmic solution)
Drug	Photrexa
Manufacturer	Glaukos
Route of Administration	Intraocular
Site of Care	Healthcare Facility
Approved Indication	The treatment of progressive keratoconus (1.1) and corneal ectasia following refractive surgery
Disease	Progressive Keratoconus; Corneal Ectasia
Therapeutic Area	Ophthalmology
Enrollment Form Link	Photrexa Enrollment Form
Phone Number	800-550-7207
Fax Number	877-277-3139
Product Website

About Idiopathic Macular Telangiectasia (MacTel) Type 2

Idiopathic macular telangiectasia (MacTel) type 2 is a rare, progressive eye disease that affects the part of the retina responsible for central vision. It typically occurs in both eyes and leads to gradual vision loss, often beginning with subtle symptoms like blurred or distorted vision. While the exact cause is unknown, genetic factors and systemic conditions like diabetes may contribute to its development.

MacTel Type 2 Therapies Supported

Full Name	ENCELTO™ (revakinagene taroretcel-lwey)
Drug	Encelto
Manufacturer	Neurotech Pharmaceuticals, Inc.
Route of Administration	Intravitreal
Site of Care	Healthcare facility
Approved Indication	Indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel)
Disease	Idiopathic macular telangiectasia type 2 (MacTel)
Therapeutic Area	Ophthalmology; Cell & Gene Therapy
Enrollment Form Link	Start Form
Phone Number	888-477-1165
Product Website	ENCELTO.com/ecp

About Progressive Keratoconus

Progressive keratoconus is a degenerative eye condition in which the cornea gradually thins and bulges into a cone-like shape. This distortion leads to increasing levels of irregular astigmatism and nearsightedness, causing blurred and distorted vision. The disease typically begins in adolescence or early adulthood and can progress into the mid-30s, often affecting both eyes to varying degrees.

Progressive Keratoconus Therapies Supported

Full Name	Photrexa® (riboflavin 5’-phosphate ophthalmic solution)
Drug	Photrexa
Manufacturer	Glaukos
Route of Administration	Intraocular
Site of Care	Healthcare Facility
Approved Indication	The treatment of progressive keratoconus (1.1) and corneal ectasia following refractive surgery
Disease	Progressive Keratoconus; Corneal Ectasia
Therapeutic Area	Ophthalmology
Enrollment Form Link	Photrexa Enrollment Form
Phone Number	800-550-7207
Fax Number	877-277-3139
Product Website